Products - Breast cancer | Topic

Showing 28 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Advanced breast cancer: diagnosis and management (Partial update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital AI tools in histopathology (breast and prostate cancer)
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 January 2026
Familial Breast Cancer: initial assessment and genetic testing (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
22 April 2027
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 June 2026
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2026
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) (TA1089)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 August 2025
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2027
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
7 May 2026
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) (TA1112)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 November 2025
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Wireless breast lesion localization using Savi Scout seed
Status:
Topic prioritisation
Programme:
Interventional procedures guidance
Expected publication date:
TBC

Breast cancer Products

Filter

Product type

Guidance programme

Status

New and updated
1 selected

Showing 28 products

Advanced breast cancer: diagnosis and management (Partial update)

Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]

Digital AI tools in histopathology (breast and prostate cancer)

Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)

Familial Breast Cancer: initial assessment and genetic testing (update)

Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]

Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) (TA1089)

Suspected Cancer: recognition and referral (update)

Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) (TA1112)

Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

Vacuum Assisted Excision for the removal of breast lesions of uncertain malignant potential

Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

Wireless breast lesion localization using Savi Scout seed

Breast cancer Products

Filter

Product type

Guidance programme

Status

New and updated1 selected

Showing 28 products

New and updated
1 selected